Takeda braces for impact as Vyvanse edges toward the patent cliff

As several of Takeda’s top-earning drugs veer toward the patent cliff, the Japanese drugmaker is buckling up for a bumpy ride. | Bracing for losses of exclusivity on a pair of drugs this year, Takeda has forecasted 3,840 billion yen (about $28.5 billion) in revenues for fiscal year 2023, an…#takeda

Source: Reuters: Health - May 13, 2023 Category: Consumer Health News Source Type: news